$80.93
7.09% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Stock price

$87.11
-2.64 2.94% 1M
-0.96 1.09% 6M
-0.11 0.13% YTD
-5.12 5.55% 1Y
+19.92 29.65% 3Y
+27.42 45.94% 5Y
+68.24 361.63% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-2.90 3.22%
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Key metrics

Market capitalization $5.57b
Enterprise Value $5.68b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.15
P/S ratio (TTM) P/S ratio 10.94
P/B ratio (TTM) P/B ratio 18.58
Revenue growth (TTM) Revenue growth 104.04%
Revenue (TTM) Revenue $508.82m
EBIT (operating result TTM) EBIT $-212.05m
Free Cash Flow (TTM) Free Cash Flow $-197.22m
Cash position $615.49m
EPS (TTM) EPS $-1.07
P/E forward negative
P/S forward 7.65
EV/Sales forward 7.80
Short interest 8.85%
Show more

Is Blueprint Medicines Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Blueprint Medicines Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Blueprint Medicines Corp. forecast:

18x Buy
75%
5x Hold
21%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Blueprint Medicines Corp. forecast:

Buy
75%
Hold
21%
Sell
4%

Financial data from Blueprint Medicines Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
509 509
104% 104%
100%
- Direct Costs 36 36
17% 17%
7%
472 472
117% 117%
93%
- Selling and Administrative Expenses 343 343
28% 28%
67%
- Research and Development Expense 325 325
22% 22%
64%
-196 -196
58% 58%
-38%
- Depreciation and Amortization 16 16
12% 12%
3%
EBIT (Operating Income) EBIT -212 -212
56% 56%
-42%
Net Profit -67 -67
87% 87%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about Blueprint Medicines Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Blueprint Medicines Corp. Stock News

Neutral
PRNewsWire
4 days ago
CAMBRIDGE, Mass. , March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m.
Neutral
PRNewsWire
about one month ago
-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy -- -- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM dise...
Neutral
Seeking Alpha
about 2 months ago
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President and Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christina Rossi - Chief Operating Officer Conferen...
More Blueprint Medicines Corp. News

Company Profile

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Kathryn Haviland
Employees 649
Founded 2008
Website www.blueprintmedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today